Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Bladder cancer
Closed
Phase 1/2
This study is looking at sacituzumab tirumotecan for non muscle invasive bladder cancer.
It is open to people with non muscle invasive bladder cancer that is and has come back after treatment.
Sacituzumab tirumotecan is also called sac-TMT and MK-2870.
You pronounce sacituzumab tirumotecan as sass-ih-too-zo-mab tie-rum-o-tee-can.
Recruitment start: 6 August 2025
Recruitment end: 23 September 2026
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Szabados
Merck Sharp & Dohme Ltd
Last reviewed: 23 Sept 2026
CRUK internal database number: 20025